Q3 2024 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Key Points
- Dishman Carbogen Amcis Ltd (BOM:540701) reported a consolidated revenue of INR651 crore for Q3 FY24, a 2% increase from the same quarter last year.
- The company achieved a 9.3% revenue growth on a nine-month basis, reaching INR1,961 crore compared to INR1,794 crore in the previous year.
- Carbogen Amcis CRAMS segment showed a 9.4% growth in Q3 FY24, with revenue increasing to INR506 crore from INR462 crore in Q3 FY23.
- The company has a strong pipeline of projects and quotations, with production planning full until the end of the summer.
- Dishman Carbogen Amcis Ltd (BOM:540701) received regulatory clearances from Japanese PMDA and EDQM, which is expected to boost the India CRAMS business significantly.
- The company faced challenges in profitability due to high exchange rates and the late start of the drug product business in France.
- There was a significant notional ForEx impact of INR76 crore in Q3 FY24, driven by the US dollar-Swiss franc currency pair movement.
- The cholesterol and vitamin D analogues business saw a dip in revenue to INR61 crore in Q3 FY24 from INR82.5 crore in Q3 FY23.
- The India Quats and Generics business experienced a slowdown due to a downturn in the chemical sector.
- Employee costs increased significantly, partly due to currency translation effects, impacting overall profitability.
Ladies and gentlemen, good day and welcome to the Dishman Carbogen Amcis Limited earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Pascal, CEO of Carbogen Amcis Limited. Thank you and over to you.
Thank you, moderator, and good afternoon, dear shareholders. Welcome to our quarterly call. Happy to be here this afternoon with you and giving you a bit of news about Dishman Carbogen Amcis and particularly Carbogen Amcis on our performance on the third quarter of this fiscal year. This third quarter was a kind of a consideration of all the efforts we are initiating in different parts of the group to go to the next level.
Paolo is going to come back on the big success we had on EDQM in September and the latest nice consequences we have on that. On the Carbogen Amcis side, despite all the challenging currency FOREX issues with the Swiss franc variance, we succeed to perform nice in quarter three results in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
